UnknownPHASE1, PHASE2NCT01717170

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Studying Intermediate uveitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Nebraska
Principal Investigator: Quan D Nguyen, MD, MSc
Truhlsen Eye Institute, University of Nebraska Medical Center
Intervention: Tocilizumab(drug)
Enrollment: 36 enrolled
Eligibility: 18-100 years · All sexes
Timeline: 2013 – 2017

Study locations (1)

Truhlsen Eye Institute, University Of Nebraska Medical Center, Omaha, Nebraska, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01717170 on ClinicalTrials.gov

← Back to all trials